NuGenerex Immuno-Oncology

The “Complete Vaccine ™”

Immunotherapy Company
Fighting Cancer and Infectious Disease

NuGenerex is a platform biotechnology company focused on harnessing the power of the immune system with a pipeline of products in development using our novel Ii-Key technology.

Read More About What We Do

SARS-CoV-2

The Virus Causing COVID-19

Introducing Our COVID Ii-Key Complete Vaccine ™

We are currently in ex-Vivo human studies for an Ii-Key SARS-CoV-2 vaccine using predictive algorithms and our proprietary Ii-Key technology platform to provide safe and long-lasting immunity from COVID-19.

Read More

AE37

Our Cornerstone Immunotherapeutic Vaccine for Cancer

AE37, Ii-Key HER2 peptide vaccine, is our lead product candidate. In a Phase IIb clinical trial with 300+ women, AE37 was shown to provide significant, long-term benefit in disease free survival for breast cancer patients with advanced disease and low HER-2.

Read More
et-waypoint et_pb_animation_right et-animated

Our COVID Ii-Key Complete Vaccine - Novel, Synthetic Ii-Key Peptide Vaccine for SARS-CoV-2

The Ii-Key technology and our proprietary vaccine discovery platform enables us to rapidly respond to emerging infectious disease threats. Our 20-year history of creating new vaccines against potentially pandemic viruses (SARS-1, Avian Influenza, Swine Flu) has positioned us to be a leader in the fight against COVID-19 with an Ii-Key-SARS-CoV-2 vaccine that is poised to enter clinical trials.
Immunotherapeutic Cancer Vaccines: Breast, Prostate, Bladder, Melanoma

Immunotherapeutic Cancer Vaccines: Breast, Prostate, Bladder, Melanoma

We have a robust clinical development program for immunotherapeutic Ii-Key vaccines including AE37 (Ii-Key-HER2) for breast, prostate and bladder cancers and Ii-Key-GP100/TYR for melanoma. AE37 has been shown in a Phase IIb clinical trial to provide significant, long-term benefit in disease free survival for breast cancer patients with advanced disease and low HER-2.
Patented, Proprietary Ii-Key Technology

Patented, Proprietary Ii-Key Targeted Technology

Our Ii-Key peptide vaccines activate the cellular T-Cell and antibody mediated response (humoral) to fight infection and provide long-term immune memory. Our amino acid (peptide) based Ii-Key products have also been proven safe and effective in hundreds of clinical trial patients.
The Complete Vaccine

The Complete Vaccine™

We believe to be truly effective, a vaccine must provide protection against acute infection as well as long-lasting immune memory. Ii-Key vaccines activate the cellular T-Cell response and generate antibodies from the humoral response to fight infection and provide long-term immunity. Our amino acid (peptide) based Ii-Key vaccines have been proven safe and effective in hundreds of clinical trial patients.

Find Out More

IMMUNOTHERAPY OF CANCER

Cancer immunotherapy uses a patient’s own immune system rather than toxic chemotherapies to target and eliminate tumors. In the last decade, antibodies, cellular therapies, and immune checkpoint inhibitors have all become the standard of care for the treatment of certain cancers. Ii-Key vaccines can work synergistically in combination with these therapies to enhance the immune response and provide long-term protection that may prevent cancer recurrence.

SEE THE SCIENCE BEHIND IT
IMMUNOTHERAPY OF CANCER

SARS-COV-2

The Virus Causing COVID-19

NuGenerex is developing an Ii-Key-SARS-CoV-2 Complete Vaccine* using predictive computer algorithms and the company’s proprietary vaccine platform to target regions of the coronavirus that can be linked with the Ii-Key to generate a Complete Vaccine providing safe and long-lasting immunity from SARS-CoV-2 infection.

Find Out More

OUR MISSION

Developing safe and effective prophylactic and immuno-therapeutic vaccines with our proprietary platform technology by supercharging and harnessing the power of the immune system to fight infectious diseases and cancer.

OUR VISION

To become the global innovative leader in combatting infectious disease and cancer; saving lives one vaccine at a time.

WHAT MAKES US DIFFERENT

  • AI Platform for biomarker discovery
  • Targeted immune system modulation
  • T-Cell activation for long-term immunity
  • Cellular and humoral (antibody) activation for a Complete Vaccine
  • Neo-antigen approaches to personalized vaccines
  • Synthetic peptide manufacturing; produce mass quantities quickly with no incubation time (100 Kg = 100 million vaccines)